Sonoma Biotherapeutics
Peter is an Associate Scientist in the discovery group at Sonoma. Prior to joining the company, he worked at Eureka Therapeutics developing solid tumor CAR-T therapies and at UCSF in the Helen Diller Cancer Center studying pancreatic cancer.
Peter is an experienced molecular biologist with extensive work constructing large-scale vector libraries for screening projects. In addition to his molecular biology work, he has a background in drug discovery, developing, and implementing phage display pipelines. He earned a BS in MCD biology from UC Santa Cruz.
This person is not in any offices
Sonoma Biotherapeutics
1 followers
Sonoma Biotherapeutics is developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases driven by an imbalanced immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted Treg cell therapies designed to induce durable immune tolerance to treat and prevent autoimmune and inflammatory diseases. Sonoma Biotherapeutics is based in South San Francisco and Seattle.